Switch theme
Sign up to access all valuation multiples
Grand Pharmaceutical Group Ltd, is an international pharmaceutical company of technological innovation. Its core businesses cover three areas: nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision interventional diagnosis and treatment technology, pharmaceutical technology, and biotechnology. Based on the pharmaceutical and biological industries, the Group focuses on the needs of patients, and technological innovation as the driving force Geographically, it derives a majority of its revenue from the PRC and also has a presence in America; Europe; and Asia other than the PRC, and others.
1995
12.0K+
LTM Revenue $1.5B
LTM EBITDA $405M
$4.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Grand Pharmaceutical has a last 12-month revenue (LTM) of $1.5B and a last 12-month EBITDA of $405M.
In the most recent fiscal year, Grand Pharmaceutical achieved revenue of $1.5B and an EBITDA of $451M.
Grand Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Grand Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| Gross Profit | $878M | XXX | $860M | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $405M | XXX | $451M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $335M | XXX | $277M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $300M | XXX | $315M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $388M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Grand Pharmaceutical's stock price is HKD 9 (or $1).
Grand Pharmaceutical has current market cap of HKD 30.3B (or $3.9B), and EV of HKD 31.6B (or $4.0B).
See Grand Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.0B | $3.9B | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Grand Pharmaceutical has market cap of $3.9B and EV of $4.0B.
Grand Pharmaceutical's trades at 2.7x EV/Revenue multiple, and 8.9x EV/EBITDA.
Equity research analysts estimate Grand Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Grand Pharmaceutical has a P/E ratio of 12.9x.
See valuation multiples for Grand Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.9B | XXX | $3.9B | XXX | XXX | XXX |
| EV (current) | $4.0B | XXX | $4.0B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.9x | XXX | 8.9x | XXX | XXX | XXX |
| EV/EBIT | 12.0x | XXX | 14.5x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 12.9x | XXX | 12.3x | XXX | XXX | XXX |
| EV/FCF | 24.6x | XXX | 24.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGrand Pharmaceutical's last 12 month revenue growth is 8%
Grand Pharmaceutical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $49K for the same period.
Grand Pharmaceutical's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Grand Pharmaceutical's rule of X is 47% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Grand Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | -3% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $49K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Grand Pharmaceutical acquired XXX companies to date.
Last acquisition by Grand Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Grand Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Grand Pharmaceutical founded? | Grand Pharmaceutical was founded in 1995. |
| Where is Grand Pharmaceutical headquartered? | Grand Pharmaceutical is headquartered in Hong Kong. |
| How many employees does Grand Pharmaceutical have? | As of today, Grand Pharmaceutical has 12.0K+ employees. |
| Who is the CEO of Grand Pharmaceutical? | Grand Pharmaceutical's CEO is Dr. Yan Shao. |
| Is Grand Pharmaceutical publicy listed? | Yes, Grand Pharmaceutical is a public company listed on HKG. |
| What is the stock symbol of Grand Pharmaceutical? | Grand Pharmaceutical trades under 00512 ticker. |
| When did Grand Pharmaceutical go public? | Grand Pharmaceutical went public in 1995. |
| Who are competitors of Grand Pharmaceutical? | Similar companies to Grand Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Grand Pharmaceutical? | Grand Pharmaceutical's current market cap is $3.9B |
| What is the current revenue of Grand Pharmaceutical? | Grand Pharmaceutical's last 12 months revenue is $1.5B. |
| What is the current revenue growth of Grand Pharmaceutical? | Grand Pharmaceutical revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Grand Pharmaceutical? | Current revenue multiple of Grand Pharmaceutical is 2.6x. |
| Is Grand Pharmaceutical profitable? | Yes, Grand Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Grand Pharmaceutical? | Grand Pharmaceutical's last 12 months EBITDA is $405M. |
| What is Grand Pharmaceutical's EBITDA margin? | Grand Pharmaceutical's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Grand Pharmaceutical? | Current EBITDA multiple of Grand Pharmaceutical is 9.9x. |
| What is the current FCF of Grand Pharmaceutical? | Grand Pharmaceutical's last 12 months FCF is $164M. |
| What is Grand Pharmaceutical's FCF margin? | Grand Pharmaceutical's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Grand Pharmaceutical? | Current FCF multiple of Grand Pharmaceutical is 24.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
